On the stage of biomedicine, full of miracles and setbacks, countless stories unfold every month. Some drugs become famous overnight, some quietly retire, and some seek a balance in controversy. As participants in this industry, we have witnessed too many turning points of "mountains and rivers turning into doubts and no way out, willows turning dark and flowers turning bright again". It is these ups and downs of stories that constitute the real picture of the development of biomedicine, and also inspire us to deeply reflect on the essence of innovation.

In August, the global biopharmaceutical field witnessed a dense burst of innovative achievements, from controversial weight loss drugs to neurological breakthroughs in precision medicine, to historic milestones in the treatment of respiratory diseases. Every case is worth savoring carefully. Let us interpret the pharmaceutical industry, where innovation and challenges coexist, from a professional perspective and calm thinking.

According to the data analysis of Yaozhiwang, a total of 722 drugs had relevant updates in August, with PD-1 being the most involved target, followed by GLP-1R and CD3. The most commonly used indication is solid tumors, followed by non-small cell lung cancer and cancer. Among them, 314 projects have advanced to the latest stage, including 216 projects conducted within China and 98 overseas projects. The top three categories of drugs are chemical drugs with a proportion of 57%, monoclonal antibodies with a proportion of 9%, and vaccines with a proportion of 6%.

In this ecosystem, there are brave scientists sweating profusely on the experimental stage, sharp investors weighing risks and returns, rigorous regulators seeking a balance between safety and efficiency, and unknown CDMOs providing solid manufacturing support behind the scenes.

I hope that the continuous success of more and more innovative drugs can better assist in providing medical assistance to more patients. Make the disease no longer dominate our life and death.

Note: The content in the article is reproduced from "news yaozh.com"